631.50SEK+0.08%Mkt Cap: —P/E: —1d ago
Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia. The company offers Buvidal, a buprenorphi…
Industry Peers
Healthcare$1.14TUSDP/E 43.0
$658.89BUSDP/E 31.7
$462.68BUSDP/E 74.0
$345.19BUSDP/E 24.7
$375.50BUSDP/E 122.7
$348.81BUSDP/E 25.0
$283.47BUSDP/E 22.7
$276.41BUSDP/E 23.7
$234.02BUSDP/E 25.0
$240.45BUSDP/E 24.5
$238.75BUSDP/E 27.4
$226.85BUSDP/E 33.1
$190.75BUSDP/E 11.3
$198.81BUSDP/E 36.9
$183.02BUSD
$160.96BUSDP/E 37.2
$142.58BUSDP/E 38.5
$151.78BUSDP/E 38.6
$142.49BUSDP/E 45.6
$130.23BUSDP/E 32.1
Key Statistics
Company
Market Cap—
Enterprise Value3.22B $
Revenue (TTM)216.82M $
Gross Profit201.80M $
Net Income (TTM)64.87M $
Revenue/Share3.636 USD
Last Price631.50 SEK
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees316
CountryGB
SectorHealthcare
Industry—
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA40.93
EV/Revenue14.86
P/S—
P/B8.04
EPS (TTM)-1.27
EPS (Forward)—
52W Range
616.2564% of range640.00
52W High640.00 SEK
52W Low616.25 SEK
Profitability
Gross Margin93.07%
Oper. Margin41.66%
EBITDA Margin36.31%
Profit Margin29.92%
ROE15.86%
ROA10.47%
Growth
Revenue Growth3.90%
Earnings Growth-1.50%
Cash Flow & Leverage
Operating CF77.72M $
CapEx (TTM)—
FCF Margin17.87%
FCF Yield—
Net Debt-378.80M $
Net Debt/EBITDA-4.81
Balance Sheet
Debt/Equity2.32
Current Ratio10.01
Quick Ratio9.35
Book Value/Sh78.65 SEK
Cash/Share68.37 SEK
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 SEK
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.38.38M
Float38.94M
Insiders33.12%
Institutions43.94%
Technical
SMA 50509.11 (+24.0%)
SMA 200384.14 (+64.4%)
Beta0.52
S&P 52W Chg18.16%
Avg Vol (30d)2.17K
Avg Vol (10d)11.54K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—